相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Competing mortality in patients diagnosed with bladder cancer: evidence of undertreatment in the elderly and female patients
A. P. Noon et al.
BRITISH JOURNAL OF CANCER (2013)
Final Results of an EORTC-GU Cancers Group Randomized Study of Maintenance Bacillus Calmette-Guerin in Intermediate- and High-risk Ta, T1 Papillary Carcinoma of the Urinary Bladder: One-third Dose Versus Full Dose and 1 Year Versus 3 Years of Maintenance
Jorg Oddens et al.
EUROPEAN UROLOGY (2013)
Prognostic factors in T1 bladder urothelial carcinoma: the value of recording millimetric depth of invasion, diameter of invasive carcinoma, and muscularis mucosa invasion
Fadi Brimo et al.
HUMAN PATHOLOGY (2013)
Long-Term Survival Outcomes with Intravesical Docetaxel for Recurrent Nonmuscle Invasive Bladder Cancer After Previous Bacillus Calmette-Guerin Therapy
LaMont J. Barlow et al.
JOURNAL OF UROLOGY (2013)
Connaught and Russian Strains Showed the Highest Direct Antitumor Effects of Different Bacillus Calmette-Guerin Substrains
Silvia Secanella-Fandos et al.
JOURNAL OF UROLOGY (2013)
Good quality white-light transurethral resection of bladder tumours (GQ-WLTURBT) with experienced surgeons performing complete resections and obtaining detrusor muscle reduces early recurrence in new non-muscle-invasive bladder cancer: validation across time and place and recommendation for benchmarking
Paramananthan Mariappan et al.
BJU INTERNATIONAL (2012)
Prognostic value of molecular markers, sub-stage and European Organisation for the Research and Treatment of Cancer risk scores in primary T1 bladder cancer
Bas W. G. van Rhijn et al.
BJU INTERNATIONAL (2012)
Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review
Mike D. Shelley et al.
BJU INTERNATIONAL (2012)
Cancer Statistics, 2012
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2012)
Treatment Options Available for Bacillus Calmette-Guerin Failure in Non-muscle-invasive Bladder Cancer
David R. Yates et al.
EUROPEAN UROLOGY (2012)
Markers Predicting Response to Bacillus Calmette-Guerin Immunotherapy in High-Risk Bladder Cancer Patients: A Systematic Review
Tahlita C. M. Zuiverloon et al.
EUROPEAN UROLOGY (2012)
A New and Highly Prognostic System to Discern T1 Bladder Cancer Substage
Bas W. G. van Rhijn et al.
EUROPEAN UROLOGY (2012)
Female Gender and Carcinoma In Situ in the Prostatic Urethra Are Prognostic Factors for Recurrence, Progression, and Disease-Specific Mortality in T1G3 Bladder Cancer Patients Treated With Bacillus Calmette-Guerin
Joan Palou et al.
EUROPEAN UROLOGY (2012)
Intracutaneous and Intravesical Immunotherapy With Keyhole Limpet Hemocyanin Compared With Intravesical Mitomycin in Patients With Non-Muscle-Invasive Bladder Cancer: Results From a Prospective Randomized Phase III Trial
Rianne J. M. Lammers et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Long-Term Decrease in Bladder Cancer Recurrence with Hexaminolevulinate Enabled Fluorescence Cystoscopy
H. Barton Grossman et al.
JOURNAL OF UROLOGY (2012)
A First in Human Phase 1 Study of CG0070, a GM-CSF Expressing Oncolytic Adenovirus, for the Treatment of Nonmuscle Invasive Bladder Cancer
James M. Burke et al.
JOURNAL OF UROLOGY (2012)
Phase 2 Study of Adjuvant Intravesical Instillations of Apaziquone for High Risk Nonmuscle Invasive Bladder Cancer
K. Hendricksen et al.
JOURNAL OF UROLOGY (2012)
Outpatient diagnostic of bladder tumours in flexible cystoscopes: Evaluation of fluorescence-guided flexible cystoscopy and bladder biopsies
Gregers G. Hermann et al.
SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY (2012)
Surveillance and Treatment of Non-Muscle-Invasive Bladder Cancer in the USA
Daniel A. Barocas et al.
ADVANCES IN UROLOGY (2012)
Confocal laser endomicroscopy for the diagnosis of urothelial bladder neoplasia: a technology of the future?
Christoph Wiesner et al.
BJU INTERNATIONAL (2011)
Long-term follow-up of T1 high-grade bladder cancer after intravesical bacille Calmette-Guerin treatment
David M. Kakiashvili et al.
BJU INTERNATIONAL (2011)
The WHO classification of 1973 is more suitable than the WHO classification of 2004 for predicting survival in pT1 urothelial bladder cancer
Wolfgang Otto et al.
BJU INTERNATIONAL (2011)
Global Cancer Statistics
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2011)
Evaluation of the Methylation Status of Tumour Suppressor Genes for Predicting Bacillus Calmette-Guerin Response in Patients With T1G3 High-Risk Bladder Tumours
Miriam Agundez et al.
EUROPEAN UROLOGY (2011)
The EORTC Tables Overestimate the Risk of Recurrence and Progression in Patients with Non-Muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guerin: External Validation of the EORTC Risk Tables
Jesus Fernandez-Gomez et al.
EUROPEAN UROLOGY (2011)
Sequential Intravesical Chemoimmunotherapy with Mitomycin C and Bacillus Calmette-Guerin and with Bacillus Calmette-Guerin Alone in Patients with Carcinoma in Situ of the Urinary Bladder: Results of an EORTC Genito-Urinary Group Randomized Phase 2 Trial (30993)
Willem Oosterlinck et al.
EUROPEAN UROLOGY (2011)
Long-term Cancer-specific Survival in Patients with High-risk, Non-muscle-invasive Bladder Cancer and Tumour Progression: A Systematic Review
Sven van den Bosch et al.
EUROPEAN UROLOGY (2011)
EAU Guidelines on Non-Muscle-Invasive Urothelial Carcinoma of the Bladder, the 2011 Update
Marko Babjuk et al.
EUROPEAN UROLOGY (2011)
The Role of a Combined Regimen With Intravesical Chemotherapy and Hyperthermia in the Management of Non-muscle-invasive Bladder Cancer: A Systematic Review
Rianne J. M. Lammers et al.
EUROPEAN UROLOGY (2011)
Frequency of Tumor Recurrence: A Strong Predictor of Stage Progression in Initially Diagnosed Nonmuscle Invasive Bladder Cancer
Nobuyuki Tanaka et al.
JOURNAL OF UROLOGY (2011)
A Review of Current Guidelines and Best Practice Recommendations for the Management of Nonmuscle Invasive Bladder Cancer by the International Bladder Cancer Group
Maurizio Brausi et al.
JOURNAL OF UROLOGY (2011)
Clinical Reliability of the 2004 WHO Histological Classification System Compared With the 1973 WHO System for Ta Primary Bladder Tumors
Federico Pellucchi et al.
JOURNAL OF UROLOGY (2011)
Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial
Savino M. Di Stasi et al.
LANCET ONCOLOGY (2011)
Narrow band imaging-assisted transurethral resection for non-muscle invasive bladder cancer significantly reduces residual tumour rate
Evelyne C. C. Cauberg et al.
WORLD JOURNAL OF UROLOGY (2011)
Cancer Statistics, 2010
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2010)
Hexaminolevulinate-Guided Fluorescence Cystoscopy in the Diagnosis and Follow-Up of Patients with Non-Muscle-Invasive Bladder Cancer: Review of the Evidence and Recommendations
J. Alfred Witjes et al.
EUROPEAN UROLOGY (2010)
Transurethral Resection of Non-Muscle-Invasive Bladder Transitional Cell Cancers With or Without 5-Aminolevulinic Acid Under Visible and Fluorescent Light: Results of a Prospective, Randomised, Multicentre Study
Martin C. Schumacher et al.
EUROPEAN UROLOGY (2010)
Impact of Routine Second Transurethral Resection on the Long-Term Outcome of Patients with Newly Diagnosed pT1 Urothelial Carcinoma with Respect to Recurrence, Progression Rate, and Disease-Specific Survival: A Prospective Randomised Clinical Trial
Rauf Taner Divrik et al.
EUROPEAN UROLOGY (2010)
Long-Term Efficacy Results of EORTC Genito-Urinary Group Randomized Phase 3 Study 30911 Comparing Intravesical Instillations of Epirubicin, Bacillus Calmette-Guerin, and Bacillus Calmette-Guerin plus Isoniazid in Patients with Intermediate- and High-Risk Stage Ta T1 Urothelial Carcinoma of the Bladder
Richard J. Sylvester et al.
EUROPEAN UROLOGY (2010)
Prognostic Accuracy of Individual Uropathologists in Noninvasive Urinary Bladder Carcinoma: A Multicentre Study Comparing the 1973 and 2004 World Health Organisation Classifications
Matthias May et al.
EUROPEAN UROLOGY (2010)
An Updated Critical Analysis of the Treatment Strategy for Newly Diagnosed High-grade T1 (Previously T1G3) Bladder Cancer
Girish S. Kulkarni et al.
EUROPEAN UROLOGY (2010)
Photodynamic Diagnosis (5-Aminolevulinic Acid) of Transitional Cell Carcinoma After Bacillus Calmette-Guerin Immunotherapy and Mitomycin C Intravesical Therapy
Ronald O. P. Draga et al.
EUROPEAN UROLOGY (2010)
Detrusor Muscle in the First, Apparently Complete Transurethral Resection of Bladder Tumour Specimen Is a Surrogate Marker of Resection Quality, Predicts Risk of Early Recurrence, and Is Dependent on Operator Experience
Paramananthan Mariappan et al.
EUROPEAN UROLOGY (2010)
Intravesical therapy for bladder cancer
Steve K. Williams et al.
EXPERT OPINION ON PHARMACOTHERAPY (2010)
Long-term Clinical Outcomes of a Phase I Trial of Intravesical Docetaxel in the Management of Non-muscle-invasive Bladder Cancer Refractory to Standard Intravesical Therapy
Melissa A. Laudano et al.
UROLOGY (2010)
Comparison of 2004 and 1973 World Health Organization Grading Systems and Their Relationship to Pathologic Staging for Predicting Long-term Prognosis in Patients With Urothelial Carcinoma
Dengfeng Cao et al.
UROLOGY (2010)
A single-institution experience with induction and maintenance intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to bacille Calmette-Guerin therapy
LaMont Barlow et al.
BJU INTERNATIONAL (2009)
Should All Patients with Non-Muscle-Invasive Bladder Cancer Receive Early Intravesical Chemotherapy after Transurethral Resection? The Results of a Prospective Randomised Multicentre Study
Sigurdur Gudjonsson et al.
EUROPEAN UROLOGY (2009)
Fluorescence Cystoscopy with High-Resolution Optical Coherence Tomography Imaging as an Adjunct Reduces False-Positive Findings in the Diagnosis of Urothelial Carcinoma of the Bladder
Joerg Schmidbauer et al.
EUROPEAN UROLOGY (2009)
An Individual Patient Data Meta-Analysis of the Long-Term Outcome of Randomised Studies Comparing Intravesical Mitomycin C versus Bacillus Calmette-Guerin for Non-Muscle-Invasive Bladder Cancer
Per-Uno Malmstrom et al.
EUROPEAN UROLOGY (2009)
Recurrence and Progression of Disease in Non-Muscle-Invasive Bladder Cancer: From Epidemiology to Treatment Strategy
Bas W. G. van Rhijn et al.
EUROPEAN UROLOGY (2009)
Recurrence, Progression, and Follow-Up in Non-Muscle-Invasive Bladder Cancer
Antoine G. van der Heijden et al.
EUROPEAN UROLOGY SUPPLEMENTS (2009)
Intravesical Mycobacterial Cell Wall-DNA Complex in the Treatment of Carcinoma In Situ of the Bladder After Standard Intravesical Therapy Has Failed
Alvaro Morales et al.
JOURNAL OF UROLOGY (2009)
Predicting Nonmuscle Invasive Bladder Cancer Recurrence and Progression in Patients Treated With Bacillus Calmette-Guerin: The CUETO Scoring Model
Jesus Fernandez-Gomez et al.
JOURNAL OF UROLOGY (2009)
Combined Thermo-Chemotherapy for Recurrent Bladder Cancer After Bacillus Calmette-Guerin
Ofer Nativ et al.
JOURNAL OF UROLOGY (2009)
Intravesical hyperthermia and mitomycin-C for carcinoma in situ of the urinary bladder: experience of the European Synergo(A (R)) working party
J. Alfred Witjes et al.
WORLD JOURNAL OF UROLOGY (2009)
Clinical Practice Recommendations for the Management of Non-Muscle Invasive Bladder Cancer
Donald Lamm et al.
EUROPEAN UROLOGY SUPPLEMENTS (2008)
Clinical Practice Recommendations for the Prevention and Management of Intravesical Therapy-Associated Adverse Events
J. Alfred Witjes et al.
EUROPEAN UROLOGY SUPPLEMENTS (2008)
A single instillation of epirubicin after transurethral resection of bladder tumors prevents only small recurrences
Ingela Berrum-Svennung et al.
JOURNAL OF UROLOGY (2008)
The global burden of urinary bladder cancer
D. Maxwell Parkin
SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY (2008)
Guideline for the management of nonmuscle invasive bladder cancer (Stages Ta, T1, and Tis): 2007 update
M. Craig Hall et al.
JOURNAL OF UROLOGY (2007)
A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer:: Low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin C
Antonio Ojea et al.
EUROPEAN UROLOGY (2007)
Phase II marker lesion study with intravesical instillation of apaziquone for superficial bladder cancer: Toxicity and marker response
Antoine G. van der Heijden et al.
JOURNAL OF UROLOGY (2006)
The effect of ofloxacin on bacillus Calmette-Guerin induced toxicity in patients with superficial bladder cancer: Results of a randomized, prospective, double-blind, placebo controlled, multicenter study
Marc Colombel et al.
JOURNAL OF UROLOGY (2006)
Final results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon α-2B for reducing recurrence of superficial bladder cancer
Fadi N. Joudi et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2006)
Can intravesical bacillus Calmette-Guerin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials
Rui Fa Han et al.
UROLOGY (2006)
Management of BCG failures in superficial bladder cancer: A review
JA Witjes
EUROPEAN UROLOGY (2006)
Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: A combined analysis of 2596 patients from seven EORTC trials
RJ Sylvester et al.
EUROPEAN UROLOGY (2006)
Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial
SM Di Stasi et al.
LANCET ONCOLOGY (2006)
Management of stage T1 tumors of the bladder: International consensus panel
AM Nieder et al.
UROLOGY (2005)
Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose?: Results of a prospective randomized trial
JA Martínez-Piñeiro et al.
JOURNAL OF UROLOGY (2005)
Bacillus Calmette-Guerin versus epirubicin for primary. secondary or concurrent carcinoma in situ of the bladder: Results of a european organization for the research and treatment of Cancer-Genito-urinary Group phase III trial (30906)
TM De Reijke et al.
JOURNAL OF UROLOGY (2005)
A second-look TUR in T1 transitional cell carcinoma:: Why?
G Jakse et al.
EUROPEAN UROLOGY (2004)
Intravesical bacillus Calmette-Guerin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials
MD Shelley et al.
BJU INTERNATIONAL (2004)
Prognosis of muscle-invasive bladder cancer: Difference between primary and progressive tumours and implications for therapy
BP Schrier et al.
EUROPEAN UROLOGY (2004)
Interim results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alfa-2b for superficial bladder cancer
MA O'Donnell et al.
JOURNAL OF UROLOGY (2004)
Preliminary European results of local microwave hyperthermia and chemotherapy treatment in intermediate or high risk superficial transitional cell carcinoma of the bladder
AG van der Heijden et al.
EUROPEAN UROLOGY (2004)
A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: A meta-analysis of published results of randomized clinical trials
RJ Sylvester et al.
JOURNAL OF UROLOGY (2004)
Maintenance bacillus Calmette-Guerin for TaT1 bladder tumors is not associated with increased toxicity: Results from a European organisation for research and treatment of cancer genito-urinary group phase III trial
APM van der Meijden et al.
EUROPEAN UROLOGY (2003)
Immune mechanisms in bacillus Calmette-Guerin immunotherapy for superficial bladder cancer
A Böhle et al.
JOURNAL OF UROLOGY (2003)
The value of a second transurethral resection in evaluating patients with bladder tumours
M Miladi et al.
EUROPEAN UROLOGY (2003)
Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: A formal meta-analysis of comparative studies on recurrence and toxicity
A Bohle et al.
JOURNAL OF UROLOGY (2003)
Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: A meta-analysis of the published results of randomized clinical trials
RJ Sylvester et al.
JOURNAL OF UROLOGY (2002)
Transurethral resection for bladder cancer using 5-aminolevulinic acid induced fluorescence endoscopy versus white light endoscopy
M Kriegmair et al.
JOURNAL OF UROLOGY (2002)
Clinically relevant improvement of recurrence-free survival with 5-aminolevulinic acid induced fluorescence diagnosis in patients with superficial bladder tumors
T Filbeck et al.
JOURNAL OF UROLOGY (2002)
Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: A combined analysis of seven EORTC studies
M Brausi et al.
EUROPEAN UROLOGY (2002)
Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Guerin with a reduced dose of 27 mg in superficial bladder cancer
JA Martínez-Piñeiro et al.
BJU INTERNATIONAL (2002)
Long-term follow-up of G3T1 transitional cell carcinoma of the bladder treated with intravesical bacille Calmette-Guerin: 18-year experience
V Pansadoro et al.
UROLOGY (2002)
A systematic review of intravesical bacillus Calmette-Guerin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer
MD Shelley et al.
BJU INTERNATIONAL (2001)
Intravesical BCG in patients with carcinoma in situ of the urinary bladder:: Long-term results of EORTC GU group phase II protocol 30861
G Jakse et al.
EUROPEAN UROLOGY (2001)
Clinical under staging of high risk nonmuscle invasive urothelial carcinoma treated with radical cystectomy
SC Dutta et al.
JOURNAL OF UROLOGY (2001)
Endoscopic detection of transitional cell carcinoma with 5-aminolevulinic acid:: Results of 1012 fluorescence endoscopies
D Zaak et al.
UROLOGY (2001)
Fluorescence endoscopy with 5-aminolevulinic acid reduces early recurrence rate in superficial bladder cancer
CR Riedl et al.
JOURNAL OF UROLOGY (2001)
What is the optimal regimen for BCG intravesical therapy? Are six weekly instillations necessary?
AR Zlotta et al.
EUROPEAN UROLOGY (2000)
Maintenance bacillus Calmette-Guerin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: A randomized Southwest Oncology Group study
DL Lamm et al.
JOURNAL OF UROLOGY (2000)
Low dose bacillus Calmette-Guerin for carcinoma in situ of the bladder: Long-term results
A Losa et al.
JOURNAL OF UROLOGY (2000)
Efficacy and safety of valrubicin for the treatment of bacillus Calmette-Guerin refractory carcinoma in situ of the bladder
G Steinberg et al.
JOURNAL OF UROLOGY (2000)
分享论文
